- About me
- Ratings & Reviews
- Urologic oncology
- Treating prostate, bladder, kidney and testicular malignancies
- Robotic and minimally invasive surgery
- Cancer staging
- Genetic epidemiology
- Early detection and management of genitourinary malignancies, and surveillance protocols for low risk prostate cancer and small renal masses
- Racial disparities in prostate cancer and other urologic malignancies
- Clinical and outcomes research pertaining to urologic malignancies
- MD, Columbia University College of Physicians and Surgeons, New York, NY
- Fellowship, Urologic Oncology, Johns Hopkins James Buchanan Brady Urological Institute, Baltimore, MD
- Residency, Urology, University of California, San Francisco, CA
- American Board of Urology
- Society of Urologic Oncology
- American Urological Association
- Mid-Atlantic Section of American Urological Association
- Philadelphia Urologic Society
- Member, Washington, DC All-Metropolitan Area Soccer Team, University of Virginia
- Echols Scholar, University of Virginia Club Soccer Team, 1999 National Champions
- Dean’s List (8/8 Semesters), University of Virginia
- Intermediate Honors, Phi Beta Kappa, Beta Chapter of Virginia
- Dean’s Day Research Award
- Herbert J. Bartlestone Award for Exceptional Accomplishments in Pharmacology
- Third Place, Clinical Research, Northern California Urological Resident Research Symposium, American Urological Association
- Second Place Gerald P. Murphy Scholar, Clinical Research, Northern California Urological Resident Research Symposium, American Urological Association
- Third Place, Joseph F. McCarthy Physician Essay Contest, Western Section American Urological Association Annual Meeting
- Second Place, Best of Poster Session, Western Section, American Urological Association Annual Meeting
- First Place, Western Section, American Urological Association
- Miley B. Wesson Resident Essay Contest
- Top Doctors, Urology, Philadelphia magazine, 2018
For patients diagnosed with urologic cancers, there are a wide range of treatment options available, and unfortunately this can be confusing to patients. My goal is to clearly explain all treatment options, and to work together with each individual patient to determine the treatment course that is best for them. It is important to consider not just the cancer, but also each patient's preferences and goals prior to settling on a treatment plan.
1. Reese AC, Casey G, Witte JS. Hereditary Prostate Cancer and Genetic Risk. In: Klein EA, Jones JS, eds. Management of Prostate Cancer, 3rd Edition. New Jersey: Humana Press, Inc., 2013.
2. Reese AC and Schoenberg MP. Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy. In: Konety BR and Chang SS. Bladder Cancer: Diagnosis and Clinical Management. Oxford, United Kingdom: Wiley-Blackwell, Inc., 2013.
3. Reese AC and Pavlovich CP. Robotic-Assisted Radical Prostatectomy: A Surgical Guide to the Extraperitoneal Approach. In: Eastham JA and Schaeffer EM. Radical Prostatectomy: Surgical Perspectives. New York, NY: Springer Science +Business Media, 2014.
4. Reese AC. Clinical and Pathologic Staging of Prostate Cancer. In: Mydlo JH and Godec CJ. Prostate Cancer, 2nd Edition. San Diego, CA: Elsevier, Inc., 2014.